Stocktoria
Nurix Therapeutics, Inc. NRIX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-07-24
Nurix Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -340.2% | -390.5% | -201.4% | -476.0% | -396.3% |
| Net margin | -314.9% | -354.9% | -187.0% | -466.9% | -393.9% |
| FCF margin | -313.7% | -333.4% | -116.6% | -445.4% | -302.6% |
| Return on assets | -38.4% | -28.9% | -40.5% | -43.3% | -24.6% |
| Return on equity | -49.1% | -36.7% | -71.8% | -59.4% | -34.2% |
| Current ratio | 7.02 | 6.46 | 3.40 | 4.51 | 4.70 |
| Revenue growth | 54.0% | -29.1% | 99.3% | 29.8% | 66.9% |
Source: SEC EDGAR filings · CIK 0001549595 · as of 2025-11-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.